

| Subject, city, state | Effective date | Subject, city, state | Effective date |
|-----------------------------|----------------|---|----------------|
| MIAMI, FL | | NEWBURY PARK, CA | |
| FLORIDA MEDICAL JOURNAL | | PEARSON, ANDROMEDA T ... | 08/20/1998 |
| CORP | 08/20/1998 | CHICAGO, IL | |
| SEMINOLE, FL | | RIBERA, ALFRED R | 08/20/1998 |
| GARY P SAZAMA PHD, PC & | | MIAMI, FL | |
| ASSOC | 08/20/1998 | RUTZ, FREDRICK D | 08/20/1998 |
| LOGAN, UT | | ATASCADERO, CA | |
| MOBILSONIX SERVICES, INC | 08/20/1998 | SASS, MICHAEL D | 08/20/1998 |
| ZEPHYRHILLS, FL | | REGO PARK, NY | |
| NORTHLAND DENTAL, INC ... | 08/20/1998 | SCHULZE, RANDALL MARTIN | 08/20/1998 |
| ANCHORAGE, AK | | SAN ANTONIO, TX | |
| PARK MANAGEMENT & RE- | | SCOTT, JOHN ELIJAH | 08/20/1998 |
| ALTY, INC | 08/20/1998 | MODESTO, CA | |
| ZEPHYRHILLS, FL | | SELKO, ROBERT L | 08/20/1998 |
| SPEED RENTAL MEDICAL, | | NOVATO, CA | |
| INC | 08/20/1998 | SHUNKWILER, KIM R | 08/20/1998 |
| MIAMI, FL | | DEARBORN HGTS, MI | |
| DEFAULT ON HEAL LOAN | | SPECTOR, MARK B | 08/20/1998 |
| ARCEFORESTIER, NESTOR .. | 08/20/1998 | CINCINNATI, OH | |
| CARMUY, PR | | TRICE, SANDRA V | 08/20/1998 |
| BRATTON, BOBBY JOE | 08/20/1998 | NASHVILLE, TN | |
| OWASSO, OK | | VANDERPOOL, KEITH B | 08/20/1998 |
| BURBANK, JOHN MARK | 08/20/1998 | WASHINGTON, DC | |
| LADY LAKE, FL | | WHITE, JEANNINE L | 08/20/1998 |
| BUTLER, KEVIN J | 08/20/1998 | SOLANA BEACH, CA | |
| ASTORIA, IL | | | |
| CALANDROS, GEORGE J | 08/20/1998 | Dated: August 5, 1998. | |
| HUNTINGTON, WV | | Joanne Lanahan, | |
| CHIAMBAS, ALEXANDER C ... | 08/20/1998 | Director, Health Care Administrative | |
| MT PROSPECT, IL | | Sanctions, Office of Inspector General. | |
| CHIODO, DANIEL J | 08/20/1998 | [FR Doc. 98-21775 Filed 8-12-98; 8:45 am] | |
| MARIETTA, GA | | BILLING CODE 4150-04-P | |
| CLARK, MARK D | 08/20/1998 | | |
| WALLA WALLA, WA | | | |
| DAVIS, MARY L | 08/20/1998 | DEPARTMENT OF HEALTH AND | |
| YPSILANTI, MI | | HUMAN SERVICES | |
| DOUNIES, THERESE M | 08/20/1998 | National Institutes of Health | |
| PALOS VERDES ESTATES, | | | |
| CA | | Government-Owned Inventions; | |
| DUONG, LINH H | 08/20/1998 | Availability for Licensing | |
| LANCASTER, PA | | | |
| ELLIS, DUNK A III | 08/20/1998 | AGENCY: National Institutes of Health, | |
| MOSS POINT, MS | | Public Health Service, DHHS. | |
| ENSIGN, LORIE A | 08/20/1998 | ACTION: Notice. | |
| SAN CLEMENTE, CA | | | |
| EVANS, CHARLES MICHAEL | 08/20/1998 | SUMMARY: The inventions listed below | |
| BECKLEY, WV | | are owned by agencies of the U.S. | |
| FEASTER, SAMUEL J | 08/20/1998 | Government and are available for | |
| ST LOUIS PARK, MN | | licensing in the U.S. in accordance with | |
| FERREIRA, TINO J | 08/20/1998 | 35 U.S.C. 207 to achieve expeditious | |
| SAN DIEGO, CA | | commercialization of results of | |
| GERMAN, CARL | 08/20/1998 | federally-funded research and | |
| SAN JOSE, CA | | development. Foreign patent | |
| GREEN, DAISY L | 08/20/1998 | applications are filed on selected | |
| SANTA BARBARA, CA | | inventions to extend market coverage | |
| HALLIDAY, JAMES W JR | 08/20/1998 | for companies and may be available for | |
| SALEM, OR | | licensing. | |
| HARRIS, CARL M | 08/20/1998 | ADDRESSES: Licensing information and | |
| HARVEY, IL | | copies of the U.S. patent applications | |
| HEINEN, JOSEPH E | 08/20/1998 | listed below may be obtained by writing | |
| COLUMBIA, SC | | to the indicated licensing contact at the | |
| KATALINICH, GERY B | 08/20/1998 | Office of Technology Transfer, National | |
| MYRTLE BEACH, SC | | Institutes of Health, 6011 Executive | |
| LASTER, YOLANDA RO- | | Boulevard, Suite 325, Rockville, | |
| CHELLE | 08/20/1998 | Maryland 20852-3804; telephone: 301/ | |
| NASHVILLE, TN | | 496-7057; fax: 301/402-0220. A signed | |
| LEE, SHERMAN T | 08/20/1998 | Confidential Disclosure Agreement will | |
| S PASADENA, CA | | | |
| NAPPI, NEIL A | 08/20/1998 | | |
| W PALM BEACH, FL | | | |
| PALMER, RICHARD M | 08/20/1998 | | |

be required to receive copies of the patent applications.

Methods and Compositions for DRM, A Protein with Cell Cycle Regulating Activity

DG Blair, PA Clausen, LZ Topol, M Marx, G Calothy.

Serial No. 60/079,440 filed 26 Mar 98.
Licensing Contact: Joseph Hemby, 301/496-7735 ext. 265.

A novel gene, DRM, has been identified whose regulation and function are linked to the cell cycle and whose over expression as a fusion with Green Fluorescent Protein (GFP) induces cell arrest at the G1/S cell cycle boundary. The expression of DRM is down regulated rapidly in transformed cells, but is highly expressed in certain normal, highly-differentiated cells of the brain, lung and colon. This novel gene may hold promise as (1) a new, early marker for cells about to transform, (2) a means for targeted cancer therapy, (3) a protective agent during chemotherapy, and (4) as a tool for *in vitro* or *in vivo* cell assays. The stabilized fluorescence of the fusion protein of DRM with GFP may be used in diagnostic assays or for basic research.

Tumor Tissue Microarrays For Rapid Molecular Profiling.

J Kononen (NHGRI), SB Leighton (NCRR), O Kallioniemi (NHGRI).
Serial No. 60/075,979 filed 25 Feb 98.

Licensing Contact: John Fahner-Vihtelic, 301/496-7735 ext. 270.

The present application describes a laboratory instrument which procures tiny (< 1 mm) core samples of biological tissue from characteristic regions of interest in paraffin embedded biological tissue blocks. The core samples are placed in a regular array in a new paraffin block creating a tissue array of thousands of selected samples for analysis. This new array block may now be sectioned, creating up to 200 nearly identical slides each containing tiny discs of the original specimens. These slides can be used as starting material for molecular screening, such as for DNA and RNA in situ hybridization as well as immunohistological staining. With this new invention, investigators are provided with a way to construct a tissue array consisting of a much higher number of tissue specimens than previously possible. Also, this new device automates the process of creating arrays and eliminates tedious hand operations while avoiding the prior art problem of extensive damage to the donor blocks. Feasibility of this method and apparatus has been proven and an automated version of the original system is in development. This research has

been published in Nature Medicine 1998 Jul 4(7): 844-847.

Inhibition of Ige-Mediated Allergies By A Human Ige-Derived Oligopeptide

EA Padlan, et al. (NIDDK).

DHHS Reference No. E-233-95/1; PCT/US97/22348 filed 05 Dec 97.

Licensing Contact: Stephen Finley, 301/496-7735 ext. 215.

It is estimated that 40 million people have some form of allergy and 14.9 million people have asthma in the United States. This technology identifies a specific amino acid sequence of the IgE molecule that when conformationally constrained inhibits the release of histamine and resulting inflammatory symptoms associated with hay fever and asthma, typical in people suffering from Type I hypersensitivity. This type of response occurs when an allergen triggers B cells to produce allergen-specific IgE antibodies. When binding to receptors on mast cells, these antibodies trigger the release of histamine and the resulting inflammatory symptoms. However when the IgE molecule is conformationally constrained by the addition of a cys residue at the amino acid terminal end and three amino acids at the carboxyl terminal end, the immune response is inhibited. The invention has applications for both of these high prevalence chronic diseases and could possibly be utilized as a vaccine for treatment of these problems.

Method of Treating Cancer Using C-26-Modified Epibryostatin

P Blumbert, Z Szallasi, GR Pettit (NCI).

Serial No. 60/013,740 filed 20 Mar 96; PCT/US97/04515 filed 30 Mar 97.

Licensing Contact: Girish Barua, 301/496-7735 ext. 263.

The invention relates to the use of 26-epibryostatin 1 and related compounds as cancer therapeutics. The compound is related to bryostatin 1 which has shown promise against melanoma but which has significant toxicity. The inventors have discovered that the antineoplastic activity of the bryostatins in a melanoma model system is not mediated by activation of protein kinase C (PKC) as previously believed. This has led to the discovery of antineoplastic activity in the lead compound, which with its reduced binding affinity for PKC would not have been expected to show such activity. The combination of antineoplastic activity with reduced affinity for PKC, which would be expected to translate into reduced toxicity compared to bryostatin 1, could lead to a significant clinical advantage

of 26-epibryostatin-1 and analogues over bryostatin 1.

Dated: July 31, 1998.

Jack Spiegel,

Director, Division of Technology Development and Transfer Office of Technology Transfer.

[FR Doc. 98-21649 Filed 8-12-98; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Mental Health; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of Mental Health Special Emphasis Panel.

Date: August 11, 1998.

Time: 1:00 p.m. to 2:30 p.m.

Agenda: To review and evaluate grant applications.

Place: Parklawn Building—Room 9C-26, 5600 Fishers Lane, Rockville, MD 20857, (Telephone Conference Call).

Contact Person: Mary Sue Krause, Scientific Review Administrator, Division of Extramural Activities, National Institute of Mental Health, NIH, Parklawn Building, 5600 Fishers Lane, Room 9C-26, Rockville, MD 20857, 301-443-6470.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

(Catalogue of Federal Domestic Assistance Program Nos. 93.242, Mental Health Research Grants; 93.281, Scientific Development Award, Scientist Development Award of Clinicians, and Research Scientist Award; 93.282, Mental Health National Research Service Awards for Research Training, National Institutes of Health, HHS)

Dated: August 7, 1998.

LaVerne Y. Stringfield,

Committee Management Officer, NIH.

[FR Doc. 98-21647 Filed 8-12-98; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Mental Health; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The contract proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the contract proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of Mental Health Special Emphasis Panel.

Date: August 19, 1998.

Time: 9:00 AM to 5:00 PM.

Agenda: To review and evaluate contract proposals.

Place: Hyatt Regency Bethesda, One Bethesda Metro Center, Bethesda, MD 20814.

Contact Person: Ron Schoenfeld, PHD, Scientific Review Administrator, Division of Extramural Activities, National Institute of Mental Health, NIH, Parklawn Building, 5600 Fishers Lane, Room 9-101, Rockville, MD 20857, 301-443-3936.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

Name of Committee: National Institute of Mental Health Special Emphasis Panel.

Date: August 21, 1998.

Time: 9:00 AM to 5:00 PM.

Agenda: To review and evaluate contract proposals.

Place: Hyatt Regency Bethesda, One Bethesda Metro Center, Bethesda, MD 20814.

Contact Person: Ron Schoenfeld, PHD, Scientific Review Administrator, Division of Extramural Activities, National Institute of Mental Health, NIH, Parklawn Building, 5600 Fishers Lane, Room 9-101, Rockville, MD 20857, 301-443-3936.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

Name of Committee: National Institute of Mental Health Special Emphasis Panel.

Date: August 25, 1998.

Time: 10:00 AM to 3:00 PM.

Agenda: To review and evaluate contract proposals.

Place: Ritz-Carlton Hotel at Pentagon City, 1250 South Hayes Street, Arlington, VA 22202.

Contact Person: Susan M Matthews, Scientific Review Administrator, Division of Extramural Activities, National Institute of